港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,606.246

-86.870-5.13%

涨家数：- -

跌家数：7

平家数：1

市盈率：- -

高：1,725.495

开：1,693.116

低：1,596.227

收：1,693.116

数据加载中...

康龙化成(03759)提名万璇为第三届董事会非执行董事候选人

康龙化成拟委任万璇为非执行董事

康龙化成(03759.HK)一季度净利增32.54%至3.06亿元新签订单金额同比增长超10%

石药集团(01093.HK)新药SYH2068注射液获准开展临床试验

阿斯达克财经

长春金赛药业有限责任公司药品申请临床试验默示许可获受理

江苏威凯尔医药科技股份有限公司药品申请临床试验默示许可获受理

山东京卫制药有限公司药品申请临床试验默示许可获受理

安徽中盛溯源生物科技有限公司药品申请临床试验默示许可获受理

和径医药科技（上海）有限公司药品申请临床试验默示许可获受理

四川美大康佳乐药业有限公司药品申请临床试验默示许可获受理

士泽生物医药（上海）有限公司药品申请临床试验默示许可获受理

瑞博生物港交所递表小核酸药物龙头企业有望登陆资本市场

泰格医药获易方达基金增持37.21万股每股作价约26.19港元

药明康德获融资买入1.47亿元，近三日累计买入5.83亿元

据华尔街日报：美国食品药品监督管理局（FDA）要求疫苗生产商诺瓦瓦克完成新一轮临床试验，以推进延迟推出的新冠病毒疫苗。

【石药集团(01093.HK)：SYH2068注射液(双链小干扰RNA药物)获临床试验批准】石药集团(01093.HK)发布公告，本集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA (si RNA)药物)(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。

石药集团(01093)：SYH2068注射液(双链小干扰RNA药物)获临床试验批准

易方达基金增持泰格医药(03347)37.21万股每股作价约26.19港元

智通财经网

康臣药业：收到SK-09片临床试验批准通知书

药明康德(02359)4月25日斥资2000.58万元回购34.93万股A股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1606.2461,"timestamp":1746605303362,"preClose":1693.1162,"halted":0,"volume":125803953,"delay":0,"changeRate":-0.051308,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-86.870117,"latestTime":"05-07 16:00:00","open":1693.1162,"high":1725.4948,"low":1596.227,"amount":2668796398,"amplitude":0.076349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746667800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746581400000,1746590400000],[1746594000000,1746604800000]],"pbRate":2.032534,"peRate":9.743367,"turnoverRate":0.010538,"increases":0,"decrements":7,"flats":1,"marketCap":348602656000,"floatMarketCap":150577516416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1725.4948,"amplitude":0.076349,"preClose":1693.1162,"low":1596.227,"pbRate":"2.032534","latestPrice":1606.2461,"volume":125803953,"delay":0,"open":1693.1162,"prevYearClose":1395.7731,"prevWeekClose":1741.969,"prevMonthClose":1656.921,"prevQuarterClose":1941.338,"fiveDayClose":1653.998,"twentyDayClose":1902.003,"sixtyDayClose":1520.761,"secType":"PLATE","market":"HK","turnoverRate":0.010538,"peRate":9.743367,"marketCap":348602656000,"floatMarketCap":150577516416,"timestamp":1746605303362,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":0,"down":7,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530316334","title":"康龙化成(03759)提名万璇为第三届董事会非执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2530316334","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530316334?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 18:56","pubTimestamp":1745751378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成(03759)发布公告，胡柏风已自愿辞任公司非执行董事及董事会战略委员会委员。胡柏风辞任后，彼自愿同意继续履行非执行董事及战略委员会委员的职责，直至公司股东于即将举行的公司2024年股东周年大会上选举产生新非执行董事为止。2025年4月25日，董事会审议通过了关于提名万璇为第三届董事会非执行董事候选人的议案。委任万璇为非执行董事须待股东于2024年股东周年大会上选举通过后，方可作实。待于2024年股东周年大会上委任获作实后，万璇亦将担任战略委员会委员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1576","BK1141","03759","300759"],"gpt_icon":0},{"id":"2530395984","title":"康龙化成拟委任万璇为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2530395984","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530395984?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 18:26","pubTimestamp":1745749560,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康龙化成(03759.HK)宣布，胡柏风已自愿辞任公司非执行董事及董事会战略委员会委员。胡先生辞任后，彼自愿同意继续履行非执行董事及战略委员会委员的职责，直至公司股东于即将举行的公司2024年股东周年大会上选举产生新非执行董事为止。2025年4月25日，董事会审议通过了关于提名万璇为第三届董事会非执行董事候选人的议案。委任万璇为非执行董事须待股东于2024年股东周年大会上选举通过后，方可作实。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427183103a46914f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427183103a46914f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03759"],"gpt_icon":0},{"id":"2530000436","title":"康龙化成(03759.HK)一季度净利增32.54%至3.06亿元  新签订单金额同比增长超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530000436","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530000436?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 18:14","pubTimestamp":1745748883,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康龙化成发布2025年第一季度报告，报告期内，公司实现营业收入人民币 30.99亿元，同比增长16.03%；归属于上市公司股东的净利润人民币3.06亿元，同比增长32.54%；归属于上市公司股东的扣除非经常性损益的净利润人民币 2.92亿元，同比增长56.08%，基本每股收益人民币0.1736元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27181449929806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03759","BK0216","300759","BK1141","BK1576"],"gpt_icon":0},{"id":"2530330844","title":"石药集团(01093.HK)新药SYH2068注射液获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2530330844","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530330844?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 17:47","pubTimestamp":1745747220,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA)获中国国家药品监督管理局批准，可以在内地开展临床试验。该产品适用于治疗高脂蛋白血症，通过优化序列和化学修饰的策略来实现更持久的基因沉默效果，具有预防动脉粥样硬化性心血管疾病的潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436132/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","BK1583","LU0140636845.USD","SG9999004220.SGD","LU1008478684.HKD","LU1226288170.HKD","03347","IE0008368742.USD","BK1141","LU0067412154.USD","LU0501845795.SGD","LU1152091754.HKD","LU0326950275.SGD","BK1191","LU1152091168.USD","LU1226287792.SGD","IE0008369823.USD","LU0072913022.USD","LU1960683339.HKD","LU1807302812.USD","BK1521","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1576","IE00B543WZ88.USD","BK1515","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287875.USD","01093","LU1993786604.SGD","LU1226288253.USD"],"gpt_icon":0},{"id":"2530848483","title":"长春金赛药业有限责任公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530848483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530848483?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，长春金赛药业有限责任公司联合申请药品“伏欣奇拜单抗注射液”，获得临床试验默示许可，受理号CXSL2500163。通过天眼查大数据分析，长春金赛药业有限责任公司共对外投资了17家企业，参与招投标项目743次，知识产权方面有商标信息507条，专利信息105条，此外企业还拥有行政许可85个。主要股东信息显示，长春金赛药业有限责任公司由长春高新技术产业（集团）股份有限公司持股99.5%、金磊持股0.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2530835874","title":"江苏威凯尔医药科技股份有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835874","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835874?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，江苏威凯尔医药科技股份有限公司联合申请药品“VC005片”，获得临床试验默示许可，受理号CXHL2500200。江苏威凯尔医药科技股份有限公司，成立于2010年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏威凯尔医药科技股份有限公司共对外投资了3家企业，参与招投标项目19次，知识产权方面有商标信息12条，专利信息47条，此外企业还拥有行政许可74个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09939","03347","BK1583","BK1576","BK1574","159938","BK1161","BK1515","BK1141"],"gpt_icon":0},{"id":"2530835584","title":"山东京卫制药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835584","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835584?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，山东京卫制药有限公司联合申请药品“米诺地尔泡沫剂（男用）”，获得临床试验默示许可，受理号CYHL2500041。山东京卫制药有限公司，成立于1993年，位于泰安市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，山东京卫制药有限公司共对外投资了2家企业，参与招投标项目1749次，知识产权方面有商标信息146条，专利信息129条，此外企业还拥有行政许可182个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1141","BK1191","BK1574","01477","BK1583","BK1576"],"gpt_icon":0},{"id":"2530835324","title":"安徽中盛溯源生物科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835324","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835324?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，安徽中盛溯源生物科技有限公司、中盛溯源（广州）生物科技有限公司联合申请药品“NCR201注射液”，获得临床试验默示许可，受理号CXSL2500126。安徽中盛溯源生物科技有限公司，成立于2016年，位于合肥市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，安徽中盛溯源生物科技有限公司共对外投资了5家企业，参与招投标项目11次，知识产权方面有商标信息60条，专利信息30条，此外企业还拥有行政许可11个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1583","BK1141","159837","BK1576"],"gpt_icon":0},{"id":"2530483315","title":"和径医药科技（上海）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530483315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530483315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1574","09939","03347","BK1576","BK1161","BK1515","BK1141","BK1583"],"gpt_icon":0},{"id":"2530365483","title":"四川美大康佳乐药业有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530365483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530365483?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，四川美大康佳乐药业有限公司联合申请药品“甘露醇山梨醇注射液”，获得临床试验默示许可，受理号CYHL2500033。通过天眼查大数据分析，四川美大康佳乐药业有限公司共对外投资了1家企业，参与招投标项目423次，知识产权方面有商标信息25条，专利信息22条，此外企业还拥有行政许可191个。主要股东信息显示，四川美大康佳乐药业有限公司由四川蓝剑投资管理有限公司持股100%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2530248331","title":"士泽生物医药（上海）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530248331","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530248331?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，士泽生物医药（上海）有限公司、士泽生物医药（苏州）有限公司联合申请药品“XS228细胞注射液”，获得临床试验默示许可，受理号CXSL2500121。士泽生物医药（上海）有限公司，成立于2021年，位于上海市，是一家以从事专业技术服务业为主的企业。主要股东信息显示，士泽生物医药（上海）有限公司由士泽生物医药（苏州）有限公司持股100%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1141","BK1576","161726","BK1583","399441"],"gpt_icon":0},{"id":"2530410672","title":"瑞博生物港交所递表 小核酸药物龙头企业有望登陆资本市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2530410672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530410672?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 09:32","pubTimestamp":1745717567,"startTime":"0","endTime":"0","summary":"根据招股书，瑞博生物目前有六款自研siRNA药物处于临床试验阶段，涉及七种适应症，其中四款进入2期临床试验；另有超过20个临床前资产持续推进中。血栓性疾病已成为全球主要死因之一，全球四分之一死亡与血栓性疾病相关。截止目前，全球尚未批准任何siRNA药物用于治疗慢性乙型肝炎。瑞博生物作为国内最早专注小核酸药物开发的企业之一，建立了强大的全球知识产权组合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","01477","BK1191","BK1574","BK1583","BK1141","BK1576"],"gpt_icon":0},{"id":"2530105812","title":"泰格医药获易方达基金增持37.21万股 每股作价约26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530105812","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530105812?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 08:32","pubTimestamp":1745713920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，4月22日，易方达基金增持泰格医药（03347）37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-27/doc-ineuqcqi7921881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0174","LU1146622755.USD","BK0077","300347","BK1141","BK0028","BK1583","BK0216","03347","LU1820825898.SGD","BK1576"],"gpt_icon":0},{"id":"2530070197","title":"药明康德获融资买入1.47亿元，近三日累计买入5.83亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530070197","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530070197?lang=zh_cn&edition=fundamental","pubTime":"2025-04-26 08:02","pubTimestamp":1745625759,"startTime":"0","endTime":"0","summary":"4月25日，沪深两融数据显示，药明康德获融资买入额1.47亿元，居两市第51位，当日融资偿还额2.63亿元，净卖出11536.85万元。最近三个交易日，23日-25日，药明康德分别获融资买入2.15亿元、2.21亿元、1.47亿元。融券方面，当日融券卖出5.75万股，净卖出4.46万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504260820209745aecb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504260820209745aecb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995583.HKD","LU0052750758.USD","LU1046422090.SGD","LU2045819591.USD","LU2125910500.SGD","02359","LU2242644610.SGD","BK1583","LU0320764599.SGD","BK1141","BK1576"],"gpt_icon":0},{"id":"2530164849","title":"据华尔街日报：美国食品药品监督管理局（FDA）要求疫苗生产商诺瓦瓦克完成新一轮临床试验，以推进延迟推出的新冠病毒疫苗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164849","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164849?lang=zh_cn&edition=fundamental","pubTime":"2025-04-26 03:22","pubTimestamp":1745608922,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7884860a095da688d55e8f59fb0acbc9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","159646","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2530818993","title":"【石药集团(01093.HK)：SYH2068注射液(双链小干扰RNA药物)获临床试验批准】石药集团(01093.HK)发布公告，本集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA (si RNA)药物)(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530818993","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530818993?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 19:27","pubTimestamp":1745580475,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK)发布公告，本集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA (si RNA)药物)(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25192749891416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999004220.SGD","BK1141","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1152091168.USD","BK4505","LU0326950275.SGD","LU0501845795.SGD","LU1951186391.HKD","IE00B031HY20.USD","IE0008369823.USD","BK1191","IE00BZ08YS42.EUR","LU1960683339.HKD","BK1576","LU0067412154.USD","BK4588","LU1807302812.USD","LU1008478684.HKD","03347","BK4585","BK1521","01093","LU1226288253.USD","LU1226287792.SGD","LU1226287875.USD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","RNA","BK1583","LU1152091754.HKD","BK1515","BK4139","LU0072913022.USD","LU1226288170.HKD","LU0880133367.SGD","IE00B543WZ88.USD","IE0008368742.USD","LU1226287529.USD"],"gpt_icon":0},{"id":"2530189536","title":"石药集团(01093)：SYH2068注射液(双链小干扰RNA药物)获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530189536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530189536?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 19:22","pubTimestamp":1745580178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主研发的化学1类新药SYH2068注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面优于同类型si RNA产品，展现出药物作用效果持久、安全性好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","IE0008369823.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1226287529.USD","BK1515","BK1576","LU0140636845.USD","LU0501845795.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226287875.USD","BK1141","LU1951186391.HKD","IE00BZ08YR35.GBP","LU1226288253.USD","SG9999004220.SGD","LU1152091168.USD","LU0067412154.USD","BK1191","LU1008478684.HKD","LU1807302812.USD","BK1583","BK4505","01093","IE00B543WZ88.USD","LU1960683339.HKD","RNA","LU0326950275.SGD","LU1152091754.HKD","IE0008368742.USD","LU1226288170.HKD","LU1226287792.SGD","BK1521","BK4585","03347","IE00B031HY20.USD","BK4588","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2530899551","title":"易方达基金增持泰格医药(03347)37.21万股 每股作价约26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530899551","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530899551?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 18:50","pubTimestamp":1745578200,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，易方达基金增持泰格医药(03347)37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-25/doc-ineuksvt1916276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300347","BK0077","BK1141","LU1820825898.SGD","BK1583","LU1146622755.USD","BK1576","BK0028","BK0216","BK0174","03347"],"gpt_icon":0},{"id":"2530903570","title":"康臣药业：收到SK-09片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903570","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903570?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 17:00","pubTimestamp":1745571654,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨康臣药业(01681.HK)发布公告，公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》。SK-09片为一类化学新药。根据披露，足细胞损伤相关肾脏疾病是一类以肾小球足细胞损伤为主要病理改变的肾脏疾病，包括糖尿病肾病、局灶节段性肾小球硬化、微小病变肾病等。患者常因得不到及时有效的治疗，最终进展为终末期肾病(ESRD)，对患者本人、家庭及社会医疗造成沉重负担。目前临床上缺乏针对足细胞保护的靶向疗法，SK-09片的临床研发有望为肾脏病患者提供更为精准有效的治疗新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1141","03347","01681","BK1583","BK1191","BK1576"],"gpt_icon":0},{"id":"2530702829","title":"药明康德(02359)4月25日斥资2000.58万元回购34.93万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530702829","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530702829?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 16:53","pubTimestamp":1745571218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月25日该公司斥资人民币2000.58万元回购34.93万股A股，回购价格为每股人民币56.83-57.79元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","LU2045819591.USD","BK0216","603259","LU2125910500.SGD","LU1997245177.USD","LU2495084118.USD","LU0708995583.HKD","LU0052750758.USD","399300","159982","LU0456842615.SGD","02359","LU1997244956.HKD","BK1576","LU0320764599.SGD","LU2488822045.USD","LU1046422090.SGD","LU1997245094.SGD","LU2242644610.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":194,"code":"91000000","status":"200"}]}}